
A decision by the FDA is expected in August 2022.

The ADA now recommends an individualized approach at diagnosis of diabetes as well as for adults who do not have symptoms to be screened at age 35 years.

Researchers in Poland investigated the presence and duration of ocular symptoms of patients with symptomatic COVID-19 infections.

Investigators from the Sun Yay-Sen University in Guangzhou have created a theranostic device that targets sensing rising fluid pressures within the eye to automatically deliver medication for a glaucoma patient.

The COMET-2 study is the first of three studies in the AR-15512 phase 3 registration program, with topline results expected by the second half of 2023.

The amount of light effused by these round-shaped eyeglass frames are designed to match the exact wavelength of sunlight a user would be exposed to outside.

Research to Prevent Blindness will launch the RPB/David L. Epstein Career Advancement Award in Glaucoma Research, sponsored by Aerie Pharmaceuticals.

The company, formerly known as Clover Therapeutics, intends to use the funding to advance two lead drug candidates that target molecularly-defined AMD patient subtypes.

Researchers report that the incidence of retinal vein occlusions increased in the 6 months following COVID-19 diagnosis.

Chronic staffing shortages are affecting both patient care and physicians’ well-being.

Companies are entering an exclusive licensing agreement for the development and commercialization of Brimochol PF and Carbachol PF in three new regions: Greater China, South Korea, and select Southeast Asian territories.

The company's technology allows for ECPs to detect, monitor, and treat AMD 3 years before clinical diagnosis.

A look at the latest developments in retinal disease, including clinical trials and advanced therapies.

Researchers are investigating a 3D-printed self-moisturizing contact lens that could be a catalyst for the development of next-generation contact lens-based medical devices.

Oxurion NV finds insufficient evidence of efficacy on key clinical endpoints for THR-687 in Part A of the INTEGRAL phase 2 trial; focus will now turn to an alternative candidate and trial.

New detailed, longer-term findings were presented at the 2022 ARVO meeting.

Interim data findings on spectacles using SightGlass Vision Diffusion Optics Technology were presented at ARVO 2022.

The Vision Council has also launched a grassroots regional marketing effort to reach more students and their families.

Set for May 23-28, the global initiative aims to bring attention to the global epidemic of myopia cases in children.

The organizations will partner for a 90-day campaign to promote optometry awareness.

Duo commits to a second year working together after a year of achievements in addressing myopia management among ECPs.

Five recipients will receive funding to atttend this years ARVO meeting in Denver, Colorado.

Trial data finds that CSF-1 (pilocarpine hydrochloride 0.4%), a preservative-free ophthalmic solution, met both its primary and secondary endpoints.

New activator features a single-piece eye cup and translucent design that allows for more efficient and accurate positioning in the eye.

Investigators report a correlation between the risk of 5-letter visual acuity (VA) loss at 24 months for eyes with clinically significant diabetic macular edema (CSDME) and good VA initially treated and eyes that were initially observed in routine clinical practice.

A new survey commissioned by the Contact Lens Institute found that US eye care practitioners are failing to take advantage of the opportunity to discuss contact lens options with 2 out of 3 patients. Two virtual panel discussions on May 3 will analyze the data.

Lois Schoenbrun, CAE (ret.), FAAO, previously served as executive director of the American Academy of Optometry.

Gifted by philanthropist James Grosfeld, the money will fund the launching of a pioneering research initiative as one of the largest investments of resources in the United States.


Changes in three new positions took effect this month.